Somerset Emsam Safety Data Should Be Collected To Remove Restrictions

Somerset should amass safety data on its Emsam (selegiline) patches that would allow FDA to remove dietary restrictions on all strengths of the major depression therapy, the Psychopharmacologic Drugs Advisory Committee said Oct. 26

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet